Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The company is headquartered in Lake Forest, Illinois and currently employs 58 full-time employees. The firm has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Mr. Mark Reisenauer is the Chief Executive Officer of Assertio Holdings Inc, joining the firm since 2025.
What is the price performance of ASRT stock?
The current price of ASRT is $14, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Assertio Holdings Inc?
Assertio Holdings Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Assertio Holdings Inc market cap?
Assertio Holdings Inc's current market cap is $89.8M
Is Assertio Holdings Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Assertio Holdings Inc, including 2 strong buy, 7 buy, 1 hold, 0 sell, and 2 strong sell